Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.070
+0.020 (0.66%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Evaxion Revenue
Evaxion had revenue of $7.49M in the twelve months ending June 30, 2026, up 135.86% year-over-year. In the year 2025, Evaxion had annual revenue of $7.53M with 125.12% growth. That makes Evaxion the 38,505th largest company in the world by revenue and 5,076th in the United States.
Revenue (ttm)
$7.49M
Revenue Growth
+135.86%
P/S Ratio
3.42
Revenue / Employee
$162,848
Employees
46
Market Cap
25.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.53M | 4.18M | 125.12% |
| Dec 31, 2024 | 3.34M | 3.27M | 4,480.82% |
| Dec 31, 2023 | 73.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 13.79M |
| Kyntra Bio | 4.62M |
| Seres Therapeutics | 1.88M |
| BeyondSpring | 1.88M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| aTyr Pharma | 190.00K |
EVAX News
- 8 days ago - Evaxion Biotech to present new immune data on EVX-01 at SITC 2026 - TheFly
- 8 days ago - Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting - GlobeNewsWire
- 26 days ago - Evaxion applies its AI-Immunology™ platform in autoimmune diseases - GlobeNewsWire
- 7 weeks ago - Evaxion Earnings Call Transcript: Q2 2026 - Transcripts
- 7 weeks ago - Evaxion Earnings release: Q2 2026 - Filings
- 7 weeks ago - Evaxion Slides: Q2 2026 - Filings
- 7 weeks ago - Evaxion announces business update and second quarter 2026 financial results - GlobeNewsWire
- 7 weeks ago - Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program - GlobeNewsWire